SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY 456.04+1.4%Oct 31 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Carnal Stock8/16/2006 7:42:18 PM
  Read Replies (1) of 166
 
Sirna moving on with Macular Degeneration Treatment.

100% Visual Acuity Stabilization observed in All Patient Groups Eight Weeks after a Single Dose of Sirna-027

SAN FRANCISCO, Aug. 10 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI), a leading RNAi-based therapeutics company, reported the final results from its recently completed Phase 1 trial for Sirna-027, a novel therapeutic for age-related macular degeneration (AMD). Single ascending doses of Sirna-027 were safe and well tolerated, and all 26 patients (100%) showed visual acuity stabilization eight weeks after a single injection. In addition, at the same time point, five of 26 patients (19%) experienced clinically significant improvement in visual acuity, indicated by an increase of at least three lines on an eye chart.

Three months after a single injection, 24 of 26 patients (92%) showed visual acuity stabilization, with four of 26 patients (15%) experiencing clinically significant improvement in visual acuity; only two of 26 patients (8%) experienced a reduction in visual acuity of three lines or more. Importantly, a decrease in foveal thickness was observed in some patient groups, which is an indication of biological activity of Sirna-027.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext